View Item 

Show simple item record

The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine

dc.contributor.authorOstruszka, Leo J.en_US
dc.contributor.authorShewach, Donna S.en_US
dc.date.accessioned2006-09-11T18:23:23Z
dc.date.available2006-09-11T18:23:23Z
dc.date.issued2003-10en_US
dc.identifier.citationOstruszka, Leo J.; Shewach, Donna S.; (2003). "The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine." Cancer Chemotherapy and Pharmacology 52(4): 325-332. <http://hdl.handle.net/2027.42/46929>en_US
dc.identifier.issn1432-0843en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46929
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12811514&dopt=citationen_US
dc.description.abstractCytotoxicity from the anticancer drug 2′,2′-difluoro-2′-deoxycytidine (dFdCyd) has been correlated with its incorporation into DNA. However, cytotoxicity may also result from inhibition of DNA synthesis, due to either (1) dFdCyd diphosphate-mediated inhibition of ribonucleotide reductase, or (2) direct inhibition of DNA polymerases by the 5′-triphosphate of dFdCyd (dFdCTP). To elucidate the role of DNA synthesis inhibition in the cytotoxicity of dFdCyd, we compared dFdCyd to hydroxyurea (HU), a ribonucleotide reductase inhibitor, and aphidicolin, an inhibitor of DNA polymerases, in the U251 and D54 human glioblastoma cell lines.en_US
dc.format.extent298669 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherDNTPen_US
dc.subject.otherDFdCyden_US
dc.subject.otherDNA Synthesisen_US
dc.subject.otherMedicineen_US
dc.subject.otherRibonucleotide Reductaseen_US
dc.titleThe role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidineen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical Center, 1310 E. Catherine St., Ann Arbor, MI 48109-0504, USAen_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical Center, 1310 E. Catherine St., Ann Arbor, MI 48109-0504, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12811514en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46929/1/280_2003_Article_661.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s00280-003-0661-5en_US
dc.identifier.sourceCancer Chemotherapy and Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
280_2003_Article_661.pdf
Size:
291.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.